JPRN-jRCT2080222238未知2 期
Phase II trial of YHI-1003 monotherapy in patients with advanced or relapsed gynecologic cancer
试验速览
- 阶段
- 2 期
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •(1)Patients with a histologically-diagnosed ovarian , endometric or cervical cancer
- •(2)Patients with a history of treatment with platinum-based chemotherary
- •(3)Patients who have agreed with the investigation of biomarkers
- •(4)Patients who can be treated with oral medications
- •(5)Patients with at least one measurable disease
排除标准
- •(1)Patients with a history of treatment with PI3K, AKT or mTOR inhibitor
- •(2)Patients with uncontrolled intercurrent illness
- •(3)Patients with brain metastases or suspected brain metastases
研究者
相似试验
未知
1 期
Phase I trial of YHI-1003relapsed or refractory neuroblastomaJPRN-jRCT2080222084Yakult Honsha Co., Ltd.18
未知
1 期
Phase I trial of YHI-1003 plus Bortezomib and DexamethasoneRelapsed Multiple Myeloma previously treated with BortezomibJPRN-jRCT2080221706Yakult Honsha Co., Ltd.18
进行中（未招募）
1 期
A study in patients with Myelodysplastic SyndromesMyelodysplastic SyndromesMedDRA version: 14.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2013-003235-30-ESilly S.A.140
进行中（未招募）
1 期
A study in patients with Myelodysplastic SyndromesMyelodysplastic SyndromesMedDRA version: 14.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2013-003235-30-ITEli Lilly and Company43
进行中（未招募）
1 期
A study in patients with Myelodysplastic SyndromesMyelodysplastic SyndromesMedDRA version: 17.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2013-003235-30-DEEli Lilly and Company140